Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional) | RFA TR 21 008

Frequently Asked Questions (FAQs)

What is the goal of this NIH funding opportunity?

The opportunity supports projects that shorten the rare-disease diagnostic odyssey, meaning the long period many patients experience before receiving an accurate rare disease diagnosis. The focus is on getting to the right diagnosis earlier and more consistently.

What is the official title and FOA number?

The NIH funding opportunity is titled "Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3/UH3 Clinical Trial Optional)" and the FOA number is RFA-TR-21-008.

What does the program want to change about where and how rare diseases are diagnosed?

The FOA emphasizes diagnostic strategies that do not depend only on highly specialized rare-disease centers. Instead, it prioritizes approaches that can be used earlier in the care pathway, especially in primary care and secondary care settings where many patients first seek help.

What kinds of approaches does NIH consider a good fit?

The announcement highlights practical, workflow-friendly diagnostic approaches that front-line clinicians can adopt without needing to completely restructure clinical operations. The aim is to make advanced diagnostic insight available sooner in routine care.

What are the required core components of a proposed strategy?

Proposed strategies must be multi-disciplinary and integrate three elements: (1) machine-assisted methods (such as algorithmic decision support or automated phenotype extraction), (2) genomic analysis (such as sequencing-based testing and variant interpretation), and (3) clinical consultation (expert clinical input that turns data into actionable diagnostic direction).

Does NIH want isolated tools or integrated systems?

NIH is looking for integrated diagnostic systems rather than isolated tools. Applications are expected to show how machine-assisted methods, genomic analysis, and clinical consultation work together in real clinical settings to improve diagnostic speed and accuracy while remaining feasible for everyday use.

Is a clinical trial required?

No. The FOA is labeled "Clinical Trial Optional," meaning a clinical trial may be proposed if it is appropriate for evaluating the diagnostic strategy, but it is not required.

What award mechanism is being used?

The award mechanism is a cooperative agreement using the UG3/UH3 structure.

What does the UG3/UH3 phased structure typically mean?

This structure commonly reflects a phased approach. UG3 typically supports an initial milestone-driven planning, feasibility, or early development period, and UH3 typically supports a later implementation or expansion phase if predefined milestones are met.

What does it mean that this is a cooperative agreement?

A cooperative agreement generally involves substantial NIH involvement compared with a standard grant. Based on the description provided, awardees should expect programmatic collaboration, milestone oversight, and shared governance expectations.

Which federal agency administers this opportunity?

It is administered by the National Institutes of Health (NIH).

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 93.350.

When was the FOA created and when was the original application closing date?

The FOA was created on January 15, 2021. The original application closing date listed was April 19, 2021.

Does the provided information include the award ceiling or the expected number of awards?

No. The source information provided does not specify an award ceiling or the expected number of awards. Applicants would typically need to consult the full FOA text and any related NIH notices for budget ranges, project periods, and anticipated funding levels.

What types of U.S. organizations are eligible to apply?

Eligibility is broad and includes many U.S.-based organizations and government entities. Examples listed include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (not federally recognized); tribally related housing authorities; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in that classification); for-profit organizations (including small businesses and other than small businesses); and other entities as allowed by NIH policy.

Are specific institution types explicitly highlighted as eligible?

Yes. The FOA explicitly highlights categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; regional organizations; eligible federal agencies; and U.S. territories or possessions.

Are non-U.S. (foreign) organizations eligible to apply as applicants?

No. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as applicants.

Can a non-domestic component of a U.S. organization apply?

No. Non-domestic components of U.S. organizations are not eligible to apply as applicants.

Are any international elements allowed at all?

Yes. "Foreign components" (as defined in the NIH Grants Policy Statement) are allowed. This generally means a U.S. applicant may include well-justified international elements if permitted under NIH rules and essential to the project.

Why does the FOA’s distinction between foreign applicants and foreign components matter?

It matters for teams that want to incorporate international expertise or datasets. The primary applicant organization must be U.S.-based and eligible, but certain international collaborations or resources may be included as foreign components when justified and allowable under NIH policy.

What clinical settings are prioritized for deploying these diagnostic strategies?

The FOA emphasizes approaches that can be adopted in primary care and secondary care settings, where patients commonly present earlier, rather than relying solely on specialized rare-disease centers.

What kinds of machine-assisted methods are referenced?

Examples mentioned include algorithmic decision support, automated phenotype extraction, and other computational tools that assist with diagnostic reasoning and/or identifying relevant patterns.

What kinds of genomic analysis are referenced?

Examples mentioned include sequencing-based testing and approaches to variant interpretation.

What does "clinical consultation" mean in this context?

Clinical consultation refers to expert clinical input that helps translate machine-assisted and genomic data into actionable diagnostic direction in a real clinical workflow.

What outcomes or impacts is the program trying to achieve?

The intended impact is earlier suspicion of rare disease, more targeted testing, better interpretation of genomic findings in the context of patient presentation, and smoother integration into routine workflows used by front-line providers, all with the goal of reducing time to accurate diagnosis.